(NASDAQ: IBRX) Immunitybio's forecast annual revenue growth rate of 145.99% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.85%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Immunitybio's revenue in 2025 is $31,222,000.On average, 3 Wall Street analysts forecast IBRX's revenue for 2025 to be $80,442,024,076, with the lowest IBRX revenue forecast at $73,716,456,560, and the highest IBRX revenue forecast at $86,938,110,287. On average, 3 Wall Street analysts forecast IBRX's revenue for 2026 to be $204,293,967,728, with the lowest IBRX revenue forecast at $156,744,558,434, and the highest IBRX revenue forecast at $241,484,943,902.
In 2027, IBRX is forecast to generate $434,822,944,494 in revenue, with the lowest revenue forecast at $375,113,673,825 and the highest revenue forecast at $494,532,215,163.